 |
Companies | Products |
|
|
Products | |
Diseases | |
Trials |  |
News |  |
- | Journal: Unraveling IGFBP3-mediated m6A modification in fracture healing. (Pubmed Central) - Mar 11, 2024
The IGFBP3/miR-23a-3p/SMAD5 axis plays a pivotal role in fracture healing, highlighting the relevance of m6A modification. IGFBP3's role in stabilizing miR-23a-3p expression through m6A modification offers a potential therapeutic target for enhancing fracture healing outcomes.
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Journal, PARP Biomarker, Metastases: IGFBP3 promotes resistance to Olaparib via modulating EGFR signaling in advanced prostate cancer. (Pubmed Central) - Feb 8, 2024
Inhibition of EGFR by Gefitinib suppressed growth of OlapR cells and improved Olaparib sensitivity, thereby phenocopying IGFBP3 inhibition. Collectively, our results highlight IGFBP3 and EGFR as critical mediators of Olaparib resistance.
- | Journal, Metastases: CDK12 regulates angiogenesis of advanced prostate cancer by IGFBP3. (Pubmed Central) - Jan 12, 2024
Collectively, our results highlight IGFBP3 and EGFR as critical mediators of Olaparib resistance. Finally, animal experiments were performed for in
- Lynparza (olaparib) / Merck (MSD), AstraZeneca
IGFBP3 promotes resistance to olaparib via modulating EGFR signaling in advanced prostate cancer (Section 15; Poster Board #12) - Mar 14, 2023 - Abstract #AACR2023AACR_6087;
Future work will utilize OlapR models to study how the IGFBP3/EGFR/DNA-PKcs protein complex promotes the development of resistance. Understanding the role of IGFBP3 in PARPi resistance will enhance our ability to re-sensitize resistant CRPC to PARPi therapeutics.
- | Journal: Evolutionary analysis and functional characterization reveal the role of the insulin-like growth factor system in a diversified selection of chickens (Gallus gallus). (Pubmed Central) - Mar 6, 2023
These results provide insights into the roles of the IGF system in the diversified selection of chickens. The SNPs associated with egg-laying performance, growth, and carcass traits could be used as genetic markers for breeding selection of chickens in the future.
- | Journal: IGFBP3 inhibits tumor growth and invasion of lung cancer cells and is associated with improved survival in lung cancer patients. (Pubmed Central) - Oct 19, 2022
In conclusion, overexpressed IGFBP3 in a LC cell line inhibited tumor growth and invasion. Translating from bench to bedside, investigation of clinicopathological parameters confirmed these experimental results showing that higher IGFBP3 plasma levels were associated with less aggressive tumor growth, reduced tumor spread, and improved survival of LC patients.
- IGFBP3 inhibits tumour growth and invasion of H1299 lung cancer cells and leads to improved survival in patients with lung cancer (8N) - Jun 22, 2022 - Abstract #ERS2022ERS_1387;
Overexpressed IGFBP3 in a LC cell line inhibited tumour growth and invasion. Increased IGFBP3 plasma levels in LC patients were associated with improved patient survival.
- | Preclinical, Journal: Insulin growth factor binding protein-3 enhances dental implant osseointegration against methylglyoxal-induced bone deterioration in a rat model. (Pubmed Central) - May 6, 2022
Increased IGFBP3 plasma levels in LC patients were associated with improved patient survival. This study demonstrated that IGFBP-3 could be applied as a therapeutic component in dental implants to promote the osseointegration of dental implants in patients with diabetes, which affects MGO levels.
- | Journal: IGFBP3 inhibits angiotensin II-induced aortic smooth muscle cell phenotypic switch and MMPs expression. (Pubmed Central) - Apr 1, 2022
IGFBP3 inhibited Ang II-induced mAoSMCs phenotypic switch as evidenced by increased smooth muscle actin alpha 2 (ACTA2) and myosin heavy chain 11 (MYH11) expression and decreased secreted phosphoprotein 1 (SPP1) and vimentin expression. Taken together, the present study demonstrates the role of IGFBP3 in preserving AoSMCs contractile state and reducing MMP9 activation and thus promoting elastic fiber synthesis, which provides a better understanding of the pathogenesis of TAD.
- | Journal: Cyclovirobuxine inhibits the progression of clear cell renal cell carcinoma by suppressing the IGFBP3-AKT/STAT3/MAPK-Snail signalling pathway. (Pubmed Central) - Feb 23, 2022
CVB exerted anti-ccRCC effects by blocking the IGFBP3-AKT/STAT3/MAPK-Snail pathway. Targeted inhibition of IGFBP3 with CVB treatment may become a promising therapeutic regimen for ccRCC.
- | Journal: MiR-22-3p Inhibits Proliferation and Promotes Differentiation of Skeletal Muscle Cells by Targeting IGFBP3 in Hu Sheep. (Pubmed Central) - Jan 12, 2022
The results of qPCR and immunofluorescence experiments proved that overexpression of IGFBP3 inhibited differentiation of skeletal muscle cells (p < 0.01), while the results of interfering IGFBP3 with siRNA were the opposite. These results indicate that miR-22-3p is involved in proliferation and differentiation of skeletal muscle cells by targeting IGFBP3.
- | Journal: Downregulation of LOX promotes castration-resistant prostate cancer progression via IGFBP3. (Pubmed Central) - Jan 11, 2022
The preclinical study in a mouse model suggested that introducing back LOX inhibited the progression of CRPC. In summary, we identified a new function of LOX in PCa and discovered that LOX downregulation contributed to progression via IGFBP3, and that the restoration of LOX may be a promising therapeutic strategy for PCa.
- | Journal: Senescent cells suppress innate smooth muscle cell repair functions in atherosclerosis. (Pubmed Central) - Nov 10, 2021
SNCs do so by antagonizing IGF-1 through the secretion of insulin-like growth factor-binding protein 3 (Igfbp3). These data indicate that the intermittent use of senolytic agents or IGFBP-3 inhibition in combination with lipid lowering drugs may provide therapeutic benefit in atherosclerosis.
- | BMS-345541 / BMS
Journal: Insulin-like growth factor binding protein 3 promotes radiosensitivity of oral squamous cell carcinoma cells via positive feedback on NF-κB/IL-6/ROS signaling. (Pubmed Central) - Oct 16, 2021
These data indicate that the intermittent use of senolytic agents or IGFBP-3 inhibition in combination with lipid lowering drugs may provide therapeutic benefit in atherosclerosis. Our data demonstrate that IGFBP3, a potential biomarker for radiosensitivity, promotes IR-mediated OSCC cell death by increasing ROS production through NF-κB activation and cytokine production.
- | Journal: IGFBP-3 and TGF-β inhibit growth in epithelial cells by stimulating type V TGF-β receptor (TβR-V)-mediated tumor suppressor signaling. (Pubmed Central) - Sep 7, 2021
By Western blot/phosphorimager/immunofluorescence-microscopy analyses, IGFBP-3 and TGF-β stimulate TβR-V-mediated IRS-2-dependent activation and cytoplasm-to-nucleus translocation of PP2A and PP1, resulting in dephosphorylation of p130/p107 and pRb, respectively, and growth arrest. Small molecule TGF-β enhancers, which potentiate TGF-β growth inhibition by enhancing TβR-I-TβR-II-mediated canonical signaling and thus activating TβR-V-mediated tumor suppressor signaling cascade (TβR-V/IRS-2/PP1/pRb), could be used to prevent and treat carcinoma.
- | Journal: The downregulation of IGFBP3 by TGF-β signaling in oral cancer contributes to the osteoclast differentiation. (Pubmed Central) - Apr 20, 2021
Although IGFBP3 increased the viability of murine bone marrow macrophages, the osteoclast differentiation of these cells was blocked by IGFBP3 in a dose-dependent manner. These results revealed a novel pathway for the regulation of osteoclastogenesis by oral cancer cells, which may be a new therapeutic target for osteolysis induced by oral cancer infiltrating into the bone.
- | Journal: Hsa_circ_0046263 functions as a ceRNA to promote nasopharyngeal carcinoma progression by upregulating IGFBP3. (Pubmed Central) - Mar 26, 2021
In addition, miR-133a-5p inhibition or IGFBP3 overexpression could rescue the malignant behavior induced by circ-0046263 silencing. Finally, circ-0046263 plays a tumor-promoting role in NPC to enhance malignant behavior through the miR-133a-5p/IGFBP3 axis, which could be a potential target for NPC therapy.